Transcatheter arterial chemoembolization plus atezolizumab and bevacizumab for unresectable hepatocellular carcinoma: a single-arm, phase II trial.
Kang WangHong-Ming YuYan-Jun XiangYu-Qiang ChengQian-Zhi NiWei-Xing GuoJie ShiShuang FengJian ZhaiShu-Qun ChengPublished in: Future oncology (London, England) (2022)
The therapeutic effect of transcatheter arterial chemoembolization (TACE) is limited for patients with hepatocellular carcinoma (HCC). Herein, we designed an open-label, single-arm phase II clinical trial to investigate the efficacy and safety of TACE combined with atezolizumab plus bevacizumab for patients with Barcelona Clinic Liver Cancer (BCLC) stage-B HCC. Patients will initially receive TACE. Atezolizumab and bevacizumab will be initiated 2-14 days after the first TACE session. TACE will be repeated on demand. The primary endpoint is the objective response rate. The secondary end points include overall survival, disease control rate, progression-free survival, time-to-progression and safety. The study results will provide evidence for establishing a novel therapeutic regimen for patients with unresectable HCC. Clinical Trial Registration: ChiCTR2100049829 (ChiCTR.org).
Keyphrases
- clinical trial
- phase ii
- free survival
- open label
- metastatic colorectal cancer
- end stage renal disease
- phase iii
- double blind
- newly diagnosed
- locally advanced
- ejection fraction
- liver metastases
- placebo controlled
- chronic kidney disease
- study protocol
- radiofrequency ablation
- randomized controlled trial
- squamous cell carcinoma
- radiation therapy
- rectal cancer
- working memory